🎉 M&A multiples are live!
Check it out!

Apogee Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Apogee Therapeutics and similar public comparables like Galapagos, Julphar, and Vivoryon Therapeutics.

Apogee Therapeutics Overview

About Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.


Founded

2023

HQ

United States of America
Employees

196

Financials

LTM Revenue n/a

LTM EBITDA -$240M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Apogee Therapeutics Financials

Apogee Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$240M.

In the most recent fiscal year, Apogee Therapeutics achieved revenue of n/a and an EBITDA of -$217M.

Apogee Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Apogee Therapeutics valuation multiples based on analyst estimates

Apogee Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$84.0M -$217M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$39.8M -$84.0M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Apogee Therapeutics Stock Performance

As of April 15, 2025, Apogee Therapeutics's stock price is $33.

Apogee Therapeutics has current market cap of $1.9B, and EV of $1.4B.

See Apogee Therapeutics trading valuation data

Apogee Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $1.9B XXX XXX XXX XXX $-3.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Apogee Therapeutics Valuation Multiples

As of April 15, 2025, Apogee Therapeutics has market cap of $1.9B and EV of $1.4B.

Apogee Therapeutics's trades at n/a LTM EV/Revenue multiple, and -5.9x LTM EBITDA.

Analysts estimate Apogee Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Apogee Therapeutics and 10K+ public comps

Apogee Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.4B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.6x XXX XXX XXX
P/E -10.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -8.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Apogee Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Apogee Therapeutics Valuation Multiples

Apogee Therapeutics's NTM/LTM revenue growth is n/a

Apogee Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Apogee Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Apogee Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Apogee Therapeutics and other 10K+ public comps

Apogee Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 158% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Apogee Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Apogee Therapeutics M&A and Investment Activity

Apogee Therapeutics acquired  XXX companies to date.

Last acquisition by Apogee Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Apogee Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Apogee Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Apogee Therapeutics

When was Apogee Therapeutics founded? Apogee Therapeutics was founded in 2023.
Where is Apogee Therapeutics headquartered? Apogee Therapeutics is headquartered in United States of America.
How many employees does Apogee Therapeutics have? As of today, Apogee Therapeutics has 196 employees.
Who is the CEO of Apogee Therapeutics? Apogee Therapeutics's CEO is Dr. Michael Henderson, M.D..
Is Apogee Therapeutics publicy listed? Yes, Apogee Therapeutics is a public company listed on NAS.
What is the stock symbol of Apogee Therapeutics? Apogee Therapeutics trades under APGE ticker.
When did Apogee Therapeutics go public? Apogee Therapeutics went public in 2023.
Who are competitors of Apogee Therapeutics? Similar companies to Apogee Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Apogee Therapeutics? Apogee Therapeutics's current market cap is $1.9B
What is the current EBITDA of Apogee Therapeutics? Apogee Therapeutics's last 12-month EBITDA is -$240M.
What is the current EV/EBITDA multiple of Apogee Therapeutics? Current EBITDA multiple of Apogee Therapeutics is -5.9x.
Is Apogee Therapeutics profitable? Yes, Apogee Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.